Exasperated by inter-party bickering by both democratic and republican Senators and filibustering by the Republicans, US Senate Majority Leader George Mitchell last week repeated his pledge to keep the Senate in session until a health reform bill is produced. "The Republicans can prolong this by stalling, but we're going to stay until it's done," he declared. "We're staying - I can't make it clearer or say it more directly."
Observers note that Sen Mitchell's determination to get a bill passed could well pay off, if only because of the unique situation in that no previous health reform legislation has ever progressed so far in the Congress. Should this attempt die, Sen Mitchell and others have warned, it will be a long time before any US president takes up the issue of health reform again.
A bipartisan bill similar to one already in the House, without taxes or an employer mandate, was offered last week by centrist Senators, led by John Chafee. It is backed by business but there are serious doubts about its financial provisions, and its chances are also hampered by some Republicans' desire for a new bill rather than amendments, Senate Minority Leader Robert Dole's reaction to any new plan, and the group's "floating" membership.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze